LORAZ Drug Patent Profile
✉ Email this page to a colleague
When do Loraz patents expire, and when can generic versions of Loraz launch?
Loraz is a drug marketed by Quantum Pharmics, Amneal Pharms, Chartwell Molecular, Hikma, Lupin Ltd, Pharm Assoc, Bedford, Dava Pharms Inc, Dr Reddys, Epic Pharma Llc, Hospira, Intl Medication Sys, Rising, Watson Labs, Roxane, Am Therap, Anda Repository, Ani Pharms, Aurolife Pharma Llc, Chartwell Rx, Halsey, Leading, Mutual Pharm, Oxford Pharms, Par Pharm, Sandoz, Sun Pharm Inds Ltd, Superpharm, Usl Pharma, Warner Chilcott, and Bedford Labs. and is included in sixty-seven NDAs.
The generic ingredient in LORAZ is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Loraz
A generic version of LORAZ was approved as lorazepam by SANDOZ on April 21st, 1987.
Summary for LORAZ
US Patents: | 0 |
Applicants: | 31 |
NDAs: | 67 |
Raw Ingredient (Bulk) Api Vendors: | 49 |
Patent Applications: | 4,555 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LORAZ |
Drug Sales Revenues: | Drug sales revenues for LORAZ |
DailyMed Link: | LORAZ at DailyMed |